Patents Assigned to Viela Bio, Inc.
  • Binding molecules specific for Fc?RIIA and uses thereof
    Patent number: 11746153
    Abstract: The disclosure provides Fc?RIIA-binding molecules, for example, humanized monoclonal antibodies capable of inhibiting Fc?RIIA activity, and methods of using the Fc?RIIA binding molecules, for example, in treating or preventing inflammatory, immune-mediated, or autoimmune diseases or disorders.
    Type: Grant
    Filed: March 1, 2022
    Date of Patent: September 5, 2023
    Assignee: Viela Bio, Inc.
    Inventors: Katherine Ann Vousden, Bo Chen, Gary Patrick Sims
  • ILT7 binding molecules and methods of using the same
    Patent number: 11673950
    Abstract: The present invention is directed to ILT7 binding molecules, e.g., anti-ILT7 antibodies, and methods for treating or preventing conditions and diseases associated with ILT7-expressing cells such as autoimmune diseases.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: June 13, 2023
    Assignee: Viela Bio, Inc.
    Inventors: Katherine Ann Vousden, Julie Ann Douthwaite, Melissa Marie Damschroder, Miguel Angel Sanjuan
  • ANTIBODIES TO FELINE MCDONOUGH SARCOMA (FMS)-LIKE TYROSINE KINASE 3 RECEPTOR LIGAND (FLT3L) AND USES THEREOF FOR TREATING AUTOIMMUNE AND INFLAMMATORY DISEASES
    Publication number: 20230056815
    Abstract: Provided herein are anti-FLT3L antibodies and methods of using the antibodies to treat autoimmune and other inflammatory diseases.
    Type: Application
    Filed: July 21, 2022
    Publication date: February 23, 2023
    Applicant: Viela Bio, Inc.
    Inventors: Anna HANSEN, Xiao Xiaodong, Peter Pavlik, Yan Chen, Catherine Rachel Ettinger
  • Methods of administering a composition comprising a Tn3 scaffold and a CD40L-specific monomer
    Patent number: 11555062
    Abstract: The present invention provides Tenascin-3 FnIII domain-based scaffolds that specifically bind to CD40L. The invention further provides engineered variants with increased affinity for the target. The present invention is also related to engineered scaffolds as prophylactic, diagnostic, or therapeutic agents, in particular for therapeutic uses against SLE and other autoimmune diseases and conditions.
    Type: Grant
    Filed: July 28, 2021
    Date of Patent: January 17, 2023
    Assignee: Viela Bio, Inc.
    Inventors: Anthony Coyle, Manuel Baca, Thomas Thisted, Stacey Drabic, Luba Grinberg, Shabazz Novarra, Vaheh Oganesyan, Ronald Herbst, David Kenneth Spencer
  • BINDING MOLECULES SPECIFIC FOR FCGAMMA RIIA AND USES THEREOF
    Publication number: 20220380458
    Abstract: The disclosure provides Fc?RIIA-binding molecules, for example, humanized monoclonal antibodies capable of inhibiting Fc?RIIA activity, and methods of using the Fc?RIIA binding molecules, for example, in treating or preventing inflammatory, immune-mediated, or autoimmune diseases or disorders.
    Type: Application
    Filed: March 1, 2022
    Publication date: December 1, 2022
    Applicant: VIELA BIO, INC.
    Inventors: Katherine Ann Vousden, Bo Chen, Gary Patrick Sims
  • Antibodies to Feline McDonough Sarcoma (FMS)-like tyrosine kinase 3 receptor ligand (FLT3L) and uses thereof for treating autoimmune and inflammatory diseases
    Patent number: 11512127
    Abstract: Provided herein are anti-FLT3L antibodies and methods of using the antibodies to treat autoimmune and other inflammatory diseases.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: November 29, 2022
    Assignee: Viela Bio, Inc.
    Inventors: Anna Hansen, Xiao Xiaodong, Peter Pavlik, Yan Chen, Catherine Rachel Ettinger
  • Binding molecules specific for Fc?RIIA and uses thereof
    Patent number: 11306145
    Abstract: The disclosure provides Fc?RIIA-binding molecules, for example, humanized monoclonal antibodies capable of inhibiting Fc?RIIA activity, and methods of using the Fc?RIIA binding molecules, for example, in treating or preventing inflammatory, immune-mediated, or autoimmune diseases or disorders.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: April 19, 2022
    Assignee: Viela Bio, Inc.
    Inventors: Katherine Ann Vousden, Bo Chen, Gary Patrick Sims
  • NUCLEIC ACIDS ENCODING A TN3 SCAFFOLD COMPRISING A CD40L-SPECIFIC MONOMER SUBUNIT
    Publication number: 20220089688
    Abstract: The present invention provides Tenascin-3 FnIII domain-based scaffolds that specifically bind to CD40L. The invention further provides engineered variants with increased affinity for the target. The present invention is also related to engineered scaffolds as prophylactic, diagnostic, or therapeutic agents, in particular for therapeutic uses against SLE and other autoimmune diseases and conditions.
    Type: Application
    Filed: July 28, 2021
    Publication date: March 24, 2022
    Applicant: Viela Bio, Inc.
    Inventors: Anthony COYLE, Manuel BACA, Thomas THISTED, Stacey DRABIC, Luba GRINBERG, Shabazz NOVARRA, Vaheh OGANESYAN, Ronald HERBST, David SPENCER
  • Nucleic acids encoding a Tn3 scaffold comprising a CD40L-specific monomer subunit
    Patent number: 11104720
    Abstract: The present invention provides Tenascin-3 FnIII domain-based scaffolds that specifically bind to CD40L. The invention further provides engineered variants with increased affinity for the target. The present invention is also related to engineered scaffolds as prophylactic, diagnostic, or therapeutic agents, in particular for therapeutic uses against SLE and other autoimmune diseases and conditions.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: August 31, 2021
    Assignee: VIELA BIO, INC.
    Inventors: Anthony Coyle, Manual Baca, Thomas Thisted, Stacey Drabic, Luba Grinberg, Shabazz Novarra, Vaheh Oganesyan, Ronald Herbst, David Kenneth Spencer
  • ILT7 binding molecules and methods of using the same
    Patent number: 11072652
    Abstract: The present invention is directed to ILT7 binding molecules, e.g., anti-ILT7 antibodies, and methods for treating or preventing conditions and diseases associated with ILT7-expressing cells such as autoimmune diseases.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: July 27, 2021
    Assignee: Viela Bio, Inc.
    Inventors: Katherine Ann Vousden, Julie Ann Douthwaite, Melissa Marie Damschroder, Miguel Angel Sanjuan
  • ILT7 BINDING MOLECULES AND METHODS OF USING THE SAME
    Publication number: 20200339673
    Abstract: The present invention is directed to ILT7 binding molecules, e.g., anti-ILT7 antibodies, and methods for treating or preventing conditions and diseases associated with ILT7-expressing cells such as autoimmune diseases.
    Type: Application
    Filed: March 9, 2017
    Publication date: October 29, 2020
    Applicant: Viela Bio, Inc
    Inventors: Katherine Ann VOUSDEN, Julie Ann DOUTHWAITE, Melissa Marie DAMSCHRODER, Miguel Angel SANJUAN
  • BINDING MOLECULES SPECIFIC FOR FCGAMMA RIIA AND USES THEREOF
    Publication number: 20200002415
    Abstract: The disclosure provides Fc?RIIA-binding molecules, for example, humanized monoclonal antibodies capable of inhibiting Fc?RIIA activity, and methods of using the Fc?RIIA binding molecules, for example, in treating or preventing inflammatory, immune-mediated, or autoimmune diseases or disorders.
    Type: Application
    Filed: April 28, 2017
    Publication date: January 2, 2020
    Applicant: Viela Bio, Inc.
    Inventors: Katherine Ann Vousden, Bo Chen, Gary Patrick Sims
  • CD40L-specific TN3-derived scaffolds and methods of use thereof
    Patent number: 10000553
    Abstract: The present invention provides Tenascin-3 FnIII domain-based scaffolds that specifically bind to CD40L. The invention further provides engineered variants with increased affinity for the target. The present invention is also related to engineered scaffolds as prophylactic, diagnostic, or therapeutic agents, in particular for therapeutic uses against SLE and other autoimmune diseases and conditions.
    Type: Grant
    Filed: October 10, 2012
    Date of Patent: June 19, 2018
    Assignee: Viela Bio, Inc.
    Inventors: Anthony Coyle, Manuel Baca, Thomas Thisted, Stacey Drabic, Luba Grinberg, Shabazz Novarra, Vaheh Oganesyan, Ronald Herbst, David Kenneth Spencer